Immune-mediated vincristine-induced neuropathy: Unlocking therapies

Vincristine-induced peripheral neuropathy (VIPN) is a prevalent and painful complication in cancer patients that lacks effective treatments. In this issue of JEM, Starobova et al. (2021. J. Exp. Med. https://doi.org/10.1084/jem.20201452) report that VIPN is driven by innate immune system activation,...

Descripción completa

Detalles Bibliográficos
Autores principales: Savelieff, Masha G., Feldman, Eva L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2021
Materias:
Insights
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992412/
https://www.ncbi.nlm.nih.gov/pubmed/33751022
http://dx.doi.org/10.1084/jem.20210286
_version_ 1783669366053666816
author Savelieff, Masha G.
Feldman, Eva L.
author_facet Savelieff, Masha G.
Feldman, Eva L.
author_sort Savelieff, Masha G.
collection PubMed
description Vincristine-induced peripheral neuropathy (VIPN) is a prevalent and painful complication in cancer patients that lacks effective treatments. In this issue of JEM, Starobova et al. (2021. J. Exp. Med. https://doi.org/10.1084/jem.20201452) report that VIPN is driven by innate immune system activation, a discovery that unlocks immunotherapies as potential treatments.
format Online
Article
Text
id pubmed-7992412
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-79924122021-11-03 Immune-mediated vincristine-induced neuropathy: Unlocking therapies Savelieff, Masha G. Feldman, Eva L. J Exp Med Insights Vincristine-induced peripheral neuropathy (VIPN) is a prevalent and painful complication in cancer patients that lacks effective treatments. In this issue of JEM, Starobova et al. (2021. J. Exp. Med. https://doi.org/10.1084/jem.20201452) report that VIPN is driven by innate immune system activation, a discovery that unlocks immunotherapies as potential treatments. Rockefeller University Press 2021-03-22 /pmc/articles/PMC7992412/ /pubmed/33751022 http://dx.doi.org/10.1084/jem.20210286 Text en © 2021 Savelieff and Feldman http://www.rupress.org/terms/https://creativecommons.org/licenses/by-nc-sa/4.0/This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle Insights
Savelieff, Masha G.
Feldman, Eva L.
Immune-mediated vincristine-induced neuropathy: Unlocking therapies
title Immune-mediated vincristine-induced neuropathy: Unlocking therapies
title_full Immune-mediated vincristine-induced neuropathy: Unlocking therapies
title_fullStr Immune-mediated vincristine-induced neuropathy: Unlocking therapies
title_full_unstemmed Immune-mediated vincristine-induced neuropathy: Unlocking therapies
title_short Immune-mediated vincristine-induced neuropathy: Unlocking therapies
title_sort immune-mediated vincristine-induced neuropathy: unlocking therapies
topic Insights
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992412/
https://www.ncbi.nlm.nih.gov/pubmed/33751022
http://dx.doi.org/10.1084/jem.20210286
work_keys_str_mv AT savelieffmashag immunemediatedvincristineinducedneuropathyunlockingtherapies
AT feldmaneval immunemediatedvincristineinducedneuropathyunlockingtherapies

Ejemplares similares